Kyle Battiston

Kyle joined Interface Biologics (prior to spin-out to Ripple Therapeutics) in 2016 and is a co-inventor of the Epidel technology and key to the discovery of low molecular weight prodrugs as sustained release drug delivery materials. He has a PhD from the University of Toronto in Biomaterials and Biomedical Engineering.

Kyle oversees discovery, platform and pipeline expansion opportunities for Ripple Therapeutics, leading the development of programs for new targets and therapeutic areas. He has 15+ years research and product development experience in the biomaterials, medical device, and drug delivery fields. Prior to joining Ripple therapeutics, he was co-founder of a medical device start-up developing bioresorbable soft tissue fillers for patients following breast-conserving surgery as part of breast cancer treatment as well as cosmetic applications.  Kyle is the author and contributor to 15+ peer-reviewed manuscripts, 2 book chapters, 15+ US and international patents, and 20+ conference abstracts and presentations.